Underutilization of anthracyclines in the management of HER2-overexpressing advanced breast cancer patients

被引：0
|
作者：
Montemurro, F.
Redana, S.
Valabrega, G.
Donadio, M.
Jacomuzzi, M. E.
Vietti-Ramus, G.
Clavarezza, M.
Danese, S.
Durando, A.
Venturini, M.
Aglietta, M.
机构：
[1] Inst Canc Res & Treatment, Candiolo, Italy
[2] Molinette Mauriziano Hosp, Ctr Oncol Subalpino COES, Turin, Italy
[3] Mauriziano Hosp, Turin, Italy
[4] Giovanni Bosco Hosp, Turin, Italy
[5] Ist Nazl Tumori, Senol Dis Management Team, Genoa, Italy
[6] St Anna Hosp, Turin, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI9 / XI10
页数：2
相关论文
共 50 条
  • [31] The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
    Boer R.
    Breast Cancer Research, 1 (1)
  • [32] Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells
    Seoane, S.
    Montero, J. C.
    Pandiella, A.
    Ocana, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Mechanisms of Action and Biological Significance of HER2 Mutations in HER2-Overexpressing Breast Cancer
    Boulbes, D. R.
    Jin, Q.
    Arold, S. T.
    Ladbury, J. E.
    Yu, D.
    Esteva, F. J.
    CANCER RESEARCH, 2011, 71
  • [34] Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
    Bartsch, R.
    Berghoff, A.
    Pluschnig, U.
    Bago-Horvath, Z.
    Dubsky, P.
    Rottenfusser, A.
    DeVries, C.
    Rudas, M.
    Fitzal, F.
    Dieckmann, K.
    Mader, R. M.
    Gnant, M.
    Zielinski, C. C.
    Steger, G. G.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 25 - 31
  • [35] THE ROLE OF HER3 EXPRESSION AND PTEN LOSS IN PATIENTS WITH HER2-OVEREXPRESSING METASTATIC BREAST CANCER (MBC)
    Park, Y. H.
    Jung, H. A.
    Choi, Y. L.
    Do, I. -G.
    Ahn, J. -S.
    Im, Y. -H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [36] Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
    R Bartsch
    A Berghoff
    U Pluschnig
    Z Bago-Horvath
    P Dubsky
    A Rottenfusser
    C DeVries
    M Rudas
    F Fitzal
    K Dieckmann
    R M Mader
    M Gnant
    C C Zielinski
    G G Steger
    British Journal of Cancer, 2012, 106 : 25 - 31
  • [37] An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
    Capri, G.
    Chang, J.
    Chen, S. -C.
    Conte, P.
    Cwiertka, K.
    Jerusalem, G.
    Jiang, Z.
    Johnston, S.
    Kaufman, B.
    Link, J.
    Ro, J.
    Schuette, J.
    Oliva, C.
    Parikh, R.
    Preston, A.
    Rosenlund, J.
    Selzer, M.
    Zembryki, D.
    De Placido, S.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 474 - 480
  • [38] TRASTUZUMAB (T) AND VINORELBINE (V) FOR PATIENTS (PTS) WITH HER2-OVEREXPRESSING ADVANCED BREAST CANCER (ABC). A PILOT PHASE II STUDY
    Ferrau', Francesco
    Adamo, Vincenzo
    Bordonaro, Roberto
    Caristi, Nicola
    Colina, Paolo
    D'Angelo, Alessandro
    Garipoli, Claudia
    Lavenia, Giuseppe
    Priolo, Domenico
    Rossello, Rosalba
    Tralongo, Paolo
    ANNALS OF ONCOLOGY, 2004, 15 : 25 - 25
  • [39] mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer
    Wada, Ryuichi
    Yagihashi, Soroku
    Naito, Zenya
    MOLECULAR MEDICINE REPORTS, 2016, 14 (06) : 5104 - 5110
  • [40] Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
    Valabrega, G.
    Montemurro, F.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 977 - 984
12345